1. BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank.
- Author
-
Sattar N, Ho FK, Gill JM, Ghouri N, Gray SR, Celis-Morales CA, Katikireddi SV, Berry C, Pell JP, McMurray JJ, and Welsh P
- Subjects
- Age Factors, COVID-19, Coronavirus Infections epidemiology, Coronavirus Infections transmission, Humans, Pandemics, Pneumonia, Viral epidemiology, Pneumonia, Viral transmission, Prognosis, Risk Factors, SARS-CoV-2, Sex Factors, Survival Rate, United Kingdom epidemiology, Betacoronavirus isolation & purification, Biological Specimen Banks statistics & numerical data, Body Mass Index, Coronavirus Infections mortality, Coronavirus Infections virology, Ethnicity statistics & numerical data, Pneumonia, Viral mortality, Pneumonia, Viral virology
- Abstract
Aims: We examined the link between BMI and risk of a positive test for SARS-CoV-2 and risk of COVID-19-related death among UK Biobank participants., Methods: Among 4855 participants tested for SARS-CoV-2 in hospital, 839 were positive and of these 189 died from COVID-19. Poisson models with penalised thin plate splines were run relating exposures of interest to test positivity and case-fatality, adjusting for confounding factors., Results: BMI was associated strongly with positive test, and risk of death related to COVID-19. The gradient of risk in relation to BMI was steeper in those under 70, compared with those aged 70 years or older for COVID-19 related death (P
interaction = 0.03). BMI was more strongly related to test positivity (Pinteraction = 0.010) and death (Pinteraction = 0.002) in non-whites (predominantly South Asians and Afro-Caribbeans), compared with whites., Conclusions: These data add support for adiposity being more strongly linked to COVID-19-related deaths in younger people and non-white ethnicities. If future studies confirm causality, lifestyle interventions to improve adiposity status may be important to reduce the risk of COVID-19 in all, but perhaps particularly, non-white communities., Competing Interests: Declaration of competing interest NS reports personal fees from Amgen, AstraZeneca, Eli Lilly, Novo Nordisk, Pfizer, and Sanofi, and grants and personal fees from Boehringer Ingelheim, outside the submitted work. PW reports grant from Boehringer Ingelheim outside submitted work. All other authors declare no competing interests., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF